30May

Phase 1/2 update from EVOLVE study : orva-cel, a BCMA- directed CAR T cell therapy for patients with R/R multiple myeloma

Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)- directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011)


Abstract No : 8504

Abstract Type : Oral Abstract Session

Indication : Multiple Myeloma

Intervention : Orvacabtagene autoleucel

Company : Juno Therapeutics, a Bristol-Myers Squibb company

Technology : CAR T Cell Therapy


Results:

Median pt age was 61 (range, 33–77) y; median time from diagnosis was 7.0 (range, 1.7–23.6) y, with a median of 6 (range, 3–18) prior regimens. Overall, 92% of pts were penta-exposed (2 IMiDs, 2 PIs, and an mAb); 61% of pts received bridging therapy (77% were refractory to bridging therapy). Two pts had dose-limiting toxicities: grade 3 neurological event (NE) for >7 d at 300 × 106 CAR+ T cells and grade 4 neutropenia for >28 d at 450 × 106 CAR+ T cells. Key efficacy and safety outcomes are shown in the Table. Cytokine release syndrome (CRS)/NEs were managed with tocilizumab and/or steroids (78%), anakinra (14%), and/or vasopressors (6%). Grade ≥3 anemia, neutropenia, and thrombocytopenia at 29 d occurred in 21%, 55%, and 44% of pts (median time to resolution to grade ≤2 of any cytopenia, ≤2.1 mo). Grade ≥3 infections occurred in 14%. After a median follow-up (F/U) of 5.9 mo, median progression-free survival was not reached.


Conclusion:

Orva-cel at 300, 450, and 600 × 106 CAR+ T cells demonstrated manageable safety (CRS grade ≥3: 2%; NE grade ≥3: 4%) and compelling efficacy in heavily pretreated pts with RRMM, with a 91% objective response rate (ORR) and 39% complete response (CR)/stringent CR (sCR) rate. Updated results will be presented, including minimal residual disease, durability of response, and recommended phase 2 dose.


Commentary:

In an interesting development, BMS has recently amended the protocol of the Evolve trial of orva-cel to include a cohort of patients who had progressed after prior BCMA-directed therapies (like bb2121 and jnj-4528). orva-cel has raised few questions because of a potential cannibalization from its own bb2121.


Refer to Multiple Myeloma Market report for detailed Insights.